Livzon Pharmaceutical Group Inc Class H (HK:1513)
:1513
Want to see HK:1513 full AI Analyst Report?
1513 Stock Chart & Stats
HK$30.94
-HK$0.15(-0.57%)
At close: 4:00 PM EST
HK$30.94
-HK$0.15(-0.57%)
Day’s Range― - ―
52-Week RangeHK$25.60 - HK$41.85
Previous CloseN/A
Volume226.80K
Average Volume (3M)553.85K
Market Cap
HK$30.61B
Enterprise ValueHK$23.76B
Total Cash (Recent Filing)HK$9.56B
Total Debt (Recent Filing)HK$3.59B
Price to Earnings (P/E)9.4
Beta0.72
Next Earnings
Aug 20, 2026EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend Yield4.09%
Share Statistics
EPS (TTM)0.75
Shares Outstanding299,807,130
10 Day Avg. Volume697,200
30 Day Avg. Volume553,853
Financial Highlights & Ratios
PEG Ratio-8.67
Price to Book (P/B)1.65
Price to Sales (P/S)1.97
P/FCF Ratio9.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$31.00Price Target Upside0.18% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)2.37
Revenue Forecast (FY)HK$12.28B
Bulls Say, Bears Say
Bulls Say
Profitability MarginsHigh and consistent gross, EBIT and net margins (~65%, ~22%, ~17%) indicate durable pricing power and efficient manufacturing. Over 2–6 months this supports steady cash earnings, resilience versus pricing pressure in generics/specialty pharma, and a reliable earnings base for reinvestment.
Conservative LeverageLow debt-to-equity (~0.27) and a sizeable equity base provide balance-sheet flexibility and lower refinancing risk. This conservative capital structure supports continued dividends, R&D or selective M&A without materially raising leverage, improving resilience across industry cycles.
Free Cash Flow StrengthGrowing free cash flow (~5.5% TTM) and FCF near 0.82x of net income show solid cash generation and earnings quality. Persistent FCF supports shareholder distributions, organic R&D spend and working-capital needs, enhancing long-term financial flexibility and strategic optionality.
Bears Say
Revenue DeclineA multi-year top-line decline (TTM -2.8%) signals weakening demand, pricing pressure or share loss. Sustained revenue contraction limits scale benefits, constrains reinvestment capacity and makes it harder to offset fixed costs, risking margin erosion and slower long-term growth absent a clear recovery.
Weak Cash Conversion Vs EBITOCF covers only ~44% of EBIT, implying that reported operating profits are not consistently converting to cash due to working-capital or timing issues. This raises free-cash-flow volatility risk and may constrain steady dividend funding or capex when working-capital needs rise.
Limited Balance-sheet CatalystsA stable asset base coupled with slowing growth suggests few balance-sheet levers to accelerate expansion organically. Without new product, regulatory or commercial catalysts, returns on capital may stagnate and the company could lack near-term drivers to re-accelerate revenue.
Livzon Pharmaceutical Group News
1513 FAQ
What was Livzon Pharmaceutical Group Inc Class H’s price range in the past 12 months?
Livzon Pharmaceutical Group Inc Class H lowest stock price was HK$25.60 and its highest was HK$41.85 in the past 12 months.
What is Livzon Pharmaceutical Group Inc Class H’s market cap?
Livzon Pharmaceutical Group Inc Class H’s market cap is HK$30.61B.
When is Livzon Pharmaceutical Group Inc Class H’s upcoming earnings report date?
Livzon Pharmaceutical Group Inc Class H’s upcoming earnings report date is Aug 20, 2026 which is in 114 days.
How were Livzon Pharmaceutical Group Inc Class H’s earnings last quarter?
Livzon Pharmaceutical Group Inc Class H released its earnings results on Apr 23, 2026. The company reported HK$0.745 earnings per share for the quarter, missing the consensus estimate of HK$0.825 by -HK$0.08.
Is Livzon Pharmaceutical Group Inc Class H overvalued?
According to Wall Street analysts Livzon Pharmaceutical Group Inc Class H’s price is currently Undervalued.
Does Livzon Pharmaceutical Group Inc Class H pay dividends?
Livzon Pharmaceutical Group Inc Class H pays a Annually dividend of HK$1.199 which represents an annual dividend yield of 4.09%. See more information on Livzon Pharmaceutical Group Inc Class H dividends here
What is Livzon Pharmaceutical Group Inc Class H’s EPS estimate?
Livzon Pharmaceutical Group Inc Class H’s EPS estimate is 0.73.
How many shares outstanding does Livzon Pharmaceutical Group Inc Class H have?
Livzon Pharmaceutical Group Inc Class H has 299,807,130 shares outstanding.
What happened to Livzon Pharmaceutical Group Inc Class H’s price movement after its last earnings report?
Livzon Pharmaceutical Group Inc Class H reported an EPS of HK$0.745 in its last earnings report, missing expectations of HK$0.825. Following the earnings report the stock price went down -0.213%.
Which hedge fund is a major shareholder of Livzon Pharmaceutical Group Inc Class H?
Currently, no hedge funds are holding shares in HK:1513
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Livzon Pharmaceutical Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$31.00 (0.18% Upside)
HK$31.00 (0.18% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.61%
12-Months-Change
Fundamentals
Return on Equity
14.47%
Trailing 12-Months
Asset Growth
2.44%
Trailing 12-Months
Company Description
Livzon Pharmaceutical Group Inc Class H
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.
1513 Stock 12 Month Forecast
Average Price Target
HK$31.00
▲(0.18% Upside)
Technical Analysis
The United Laboratories International Holdings
―
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---